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Persistent alteration of protein conformation due to interaction with isoﬂurane may be a novel molecular aspect of
preconditioning. We preincubated human serum albumin with isoﬂurane, dialyzed to release agent, and assessed protein
conformation. Susceptibility to chemical modiﬁcation by methylglyoxal and nitrophenylacetate was also examined. Isoﬂurane had
a persistent eﬀect on protein conformation. An increase in the susceptibility of surface residues to chemical modiﬁcation attended
this change in conformation. Modiﬁcation of isoﬂurane-treated HSA included intra- and intersubunit cross-linking that may be
a consequence of anesthetic-induced changes in multimeric subpopulations. This irreversible eﬀect of isoﬂurane may represent a
mechanism for preconditioning.
1.Introduction
The prevailing view of inhaled anesthetics is that they exhibit
their desired eﬀects on consciousness and response to pain
by binding to target neuronal proteins [1]. The speciﬁc
conformational changes that occur on binding of inhaled
anesthetics remain an area of substantial research interest.
Crystallographic and biochemical data reveal that binding
sites exhibit considerable heterogeneity [2, 3]. Nevertheless,
certain commonalities may exist [4]. The binding of inhaled
anesthetics appear to aﬀect interfacial regions in proteins
that may be at sites interfacing two domains or subunits
[1, 5]. These sites are considered to be less hydrated
than substrate binding sites [6, 7]. Occupancy of these
cavities by inhaled anesthetics may play a role in limiting
conformational exploration of proteins. We think that upon
release of anesthetic agents from these sites, a persistent
alteration in conformation may occur that contributes to
preconditioning.
The susceptibility of proteins to chemical modiﬁcation
by carbohydrate and lipid fragmentation products increases
following exposure to inhaled anesthetics [8, 9]. The current
study further explores the consequence of isoﬂurane binding
using serum albumin as a surrogate protein in order
to elucidate the eﬀects of inhaled anesthetics on protein
conformation. Human serum albumin (HSA) has several
well-characterized anesthetic-binding sites [2, 3]. We think
that the anesthetic-induced increase in susceptibility to
chemical modiﬁcation, such as glycation, may ultimately
lead to cell signals associated with preconditioning. Inter-
estingly, inhaled anesthetics upregulate heat shock proteins
[10], which are involved in repairing protein misfolds.
The unfolded protein response is thought to play a part
in conferring cellular preconditioning [11]. We previously
observed that protein unfolding increases the susceptibility
to glycation [12], suggesting that susceptibility to chem-
ical modiﬁcation is dependent upon the conformational
integrity of the protein.2 Biochemistry Research International
In the present study we tested whether glycation and
acetylation of HSA is aﬀected by isoﬂurane. Methylglyoxal
(MG), a reactive di-carbonyl, is a glycating agent elevated in
diabetics [13], and p-nitrophenylacetate (NPA) is a potent
synthetic acetylating reagent that reacts with lysine residues
that are common targets of monocarbonyl glycating agents.
Albumin exhibits an esterase-like activity [14, 15], which
recently has been redeﬁned as chemical modiﬁcation via
acetylation of multiple sites by NPA that occurs in a biphasic
manner with speciﬁc residues being sequentially modiﬁed
[16]. We also looked at the recovery of protein conforma-
tion following extensive dilution of isoﬂurane-treated HSA.
In addition to describing the appearance of a persistent
isoﬂurane-directed misfold, we discuss the role of isoﬂurane
on HSA oligomerization and MG-induced crosslinking. Our
results suggest a novel mechanism of preconditioning, which
is a curious attribute of isoﬂurane [17, 18].
2.MaterialsandMethods
2.1. Chemicals and Reagents. Unless otherwise stated, HSA
(Sigma-Aldrich; A-8763, fraction V) solutions (150μM)
were prepared in a 20mM sodium phosphate (pH 7.4)
buﬀer. Stock bottles of MG (Sigma-Aldrich; M-0252) and
isoﬂurane (Hospira Laboratories, Lake Forest, IL; lot #35-
526-DK) were used within three months after opening; MG
(40% in water) was kept at 4◦C and isoﬂurane was purged
with nitrogen gas following use. p-Nitrophenylacetate (NPA)
was purchased from Sigma (N8130) and freshly pre-
pared (37.5% acetone) for each experiment. 8-Anilino-
1-naphthalene sulphonic acid (ANS) was from Sigma.
Water was deionized using Millipore’s Milli-Q system to
18.2MΩ/cm. All other chemicals were of reagent grade or
better.
2.2. Exposure of HSA to Isoﬂurane. Unless otherwise indi-
cated, HSA (950μL of 150μM) was treated with isoﬂurane
(500μL) at room temperature by gently mixing in air-
tight vials (Supelco) for 30min prior to brief centrifugation
and removal of upper aqueous phase containing HSA.
Isoﬂurane is immiscible in water with a preference for
the gas phase. The aqueous isoﬂurane concentrations were
thereforedeterminedusingtheidealgaslawandthepartition
coeﬃcient for isoﬂurane in water/gas as described in [19].
Brieﬂy, the partial pressure of isoﬂurane (ppI) in the air
compartment of the vial (gVi) was calculated using the
following equation:
ppI = gVi ×760mmHg. (1)
T h ei d e a lg a sl a w ,PV = nRT,w h e r eP is ppI, V is volume
of the headspace (hsV), T is temperature in kelvins, and R is
the gas constant (62.363L·mmHg· ◦K−1 ·mol−1), was used
to determine the number of moles of isoﬂurane in the gas
compartment (n(g)):
n

g

=

ppI

·hsV

RT
. (2)
The water/gas partition coeﬃcient (λw) for isoﬂurane was
used to calculate the amount of moles of isoﬂurane in the
water compartment (n(w)):
λw =

(n(w))

n

g


. (3)
The concentration of isoﬂurane in the water compartment
(C(w)) was obtained by dividing the number of moles
of isoﬂurane (n(w)) by the volume in liters of the water
compartment (lVw)i nt h ev i a la n da d j u s t e dt om Ma s
indicated in the following equation:
C(w) =

n(w)
lVw

· 103. (4)
Under these treatment conditions (950μL of HSA at 150μM
and 500μL of isoﬂurane) with a deﬁned headspace, the
calculated concentration of aqueous isoﬂurane was 0.3mM.
2.3.ANSBindingAssay. FollowingtreatmentofHSA(900μL
of 75μM HSA with 300μLi s o ﬂ u r a n ef o r1 . 7 5 h ra tr o o m
temperature), which calculated to an isoﬂurane concen-
tration of 0.4mM, samples (600μL) were dialyzed against
500mLsodiumphosphatebuﬀer(20mM,pH7.4)overnight
with one change in dialysis medium. Dialysis was performed
to remove bound isoﬂurane. Samples were then tested
for ANS binding using ﬂuorescence spectroscopy. HSA
(1.5μM)wasincubatedwithANS(20μM)priortoobtaining
ﬂuorescence emission spectra from 400 to 600nm with
excitation at 360nm, slit 10nm. Background ANS emission
was subtracted from resulting spectra. In determining the
areas under the curves, intensities were integrated over the
full range (400–600nm), and controls were compared to
isoﬂurane-treated samples using Student’s t-test.
2.4. Dilution of Isoﬂurane-Treated HSA. The eﬀects of dilu-
tion of HSA on the release of isoﬂurane following treat-
ment were examined using intrinsic protein ﬂuorescence.
HSA contains a single tryptophan residue (W214) that
allows for assessment of protein conformation. Isoﬂurane
aﬀects ﬂuorescence spectra [5, 9], allowing for an indirect
measurement of bound isoﬂurane. Spectra of samples of
HSA (150μM) that were treated with isoﬂurane (0.4mM
for 35min at room temperature) were obtained before and
after extensive dilution. Emission spectra of samples were
determined at 310–430nm (slit 2.5nm) with excitation
at 293nm (slit 2.5nm). Values for the center of spectral
mass were calculated from the emission spectra using the
equation:
CSM =

(νFi)di
Fidi
, i = 33.3cm −1,( 5 )
where(ν)iswa v e n umbe rand(Fi)isemission intensity. They
indicate spectral position and reﬂect the conformational
events that change hydration at the W214 [20], suggesting
conformational and oligomeric changes [5].Biochemistry Research International 3
2.5. HSA Acetylation. Spectrophotometric assays were used
to track the release of nitrophenol, which absorbs at 401nm,
following the acetylation of HSA by NPA. Solvent-directed
hydrolysisofNPAwasdeterminedintheabsenceofHSAand
subtracted from calculated acetylation rates. There were two
phases of HSA acetylation: an early burst phase following by
a late slow steady-state phase. The analysis of the early burst
phase gave kinetics of acetylation rates of the residue Y411
[16]. This rate is equivalent to that was previously thought
to be associated with burst-phase esterase activity [14]. The
rate constant for Y411 acetylation was determined using the
following second-order rate constant equation generating a
straight line with the slope equal to k2:
log
	 (NPAi −NP)
(HSAi −HSA-A)


=

NPAi −HSAi
2.3

k2t
−log

HSAi
NPAi

,
(6)
where NPAi is the initial concentration of NPA, NP is the
released nitrophenol measured over time, HSAi is the initial
concentration of HSA, HSA-A is the acetylated HSA, k2 is
the second order rate constant (M−1 min−1), and t is time
(min). Maximum Y411 acetylation was determined from the
y-intercept of the curve extrapolation. The late slow steady-
state release of NP was used to measure the rate of surface
residue acetylation using pseudoﬁrst-order kinetics:
dNP
dt
= k
 
1[NPA] (7)
to determine k
 
1 (1/min) after subtracting solvent-directed
NPA hydrolysis.
2.6. Modiﬁcation by MG. Control and isoﬂurane-treated
samples of HSA (15μM) were then incubated with MG (0,
150, and 300μM MG for 18hr at room temperature) under
constant mixing in a 20mM sodium phosphate, pH 7.4
buﬀer containing 1% methanol as an antimicrobial agent.
Samples were then dialyzed (Spectrum Laboratories Rancho
Dominguez, CA) using a Spectra/Por CE, 10kDa MWCO
(1:1000) against buﬀer for 3.5hr prior to analysis.
2.7. AGE Fluorescence. HSA samples were treated and incu-
bated as described above, and MG-induced ﬂuorescence due
toproteinboundadvancedglycationendproducts(AGEs)[9,
21]wasmeasuredfromemissionspectrathatwereintegrated
over 380–500nm (slit: 2.5nm) with excitation at 330nm
(slit: 5nm). Duplicate scans were averaged using a speed of
400nm/minwiththeﬁltercutoﬀsettoopen.Dataweregiven
in relative ﬂuorescence units (rfu).
2.8.SDSPAGE. Controlandisoﬂurane-treatedHSAsamples
that were incubated with and without MG were dialyzed as
described above and were electrophoresed under denaturing
conditions using precast (Bio-Rad; Hercules, CA) Tris-HCl
gels (7.5% polyacrylamide). Gels were run at constant
voltage of 200V, set at 60mA for 45min, ﬁxed in 10% TCA,
stained with Coomassie Blue R-250, and destained in 7%
acetic acid, 10% methanol. The gels were then scanned and
processed using SigmaGel, setting threshold levels at ﬁxed
points from baseline and integrating intensities.
2.9. Statistical Analysis. Student’s t-tests (two-tailed, unless
otherwise indicated) were conducted using SigmaPlot, 9.0
or Excel to determine signiﬁcant diﬀerences using a 95%
conﬁdence limit. Linear regression analysis was done using
SigmaPlot, and Pearson r coeﬃcients were assessed using
standard reference tables applying a two-tailed test. One-way
ANOVA and Bonferroni post hoc tests were performed using
SigmaStat to compare the blank data to the sample means.
3. Results
3.1.Isoﬂurane-InducedPersistentMisfoldofHSA. Afterexpo-
sure of HSA (0.4mM of isoﬂurane for 1.75hr at room
temperature under gentle agitation) and then dialysis to
remove bound isoﬂurane, we observed a persistent change in
protein conformation (Figure 1) as represented by increased
ANS binding. This suggests that upon isoﬂurane release
from their HSA binding sites, hydrophobic regions remained
accessible.
In a separate experiment, we diluted isoﬂurane-exposed
HSA by greater than 30-fold (calculated ﬁnal concentration
of isoﬂurane: <10nM) prior to measuring intrinsic ﬂuo-
rescence. Undiluted HSA (150μM), which was pretreated
with isoﬂurane (0.4mM for 35min at room temperature),
exhibited a large spectral diﬀerence relative to control
(Figure 2(a)). Upon dilution, we observed that total ﬂuo-
rescence intensity fell below 100% of control (Figure 2(b))
suggestingthatcompleterecoveryofnativeconformationdid
not occur. It also appeared that the spectra of the diluted,
treated samples were red-shifted relative to control (CSM
values: 28927.6, control versus 28664.9cm−1,i s o ﬂ u r a n e ) ,
suggesting improper refolding of HSA upon isoﬂurane
release. It is important to note that upon isoﬂurane binding
to HSA, there is a blue-shift in the spectra (Figure 2(a)),
indicatingthereleaseofisoﬂuranecausedastructuralchange
in the area associated with the anesthetic binding site as the
protein refolds.
3.2. Acetylation of HSA Residue Y411. NPA acetylates residue
Y411 of HSA as measured by burst phase analysis described
in Section 2. We tested the eﬀects of isoﬂurane on Y411
acetylation. HSA (150μM) was ﬁrst treated with isoﬂurane
(0.5mM for 70min at room temperature), diluted 30-
fold, and analyzed immediately (<20min) for NPA-induced
acetylation.Weobservedthatisoﬂuraneinhibitedacetylation
of Y411 (Figure 3, black bars). The control rate constant
(k2) from immediate analysis was 566 ± 56 versus isoﬂurane
treated (330 ± 14M−1 min−1, P<0.05). Interestingly, when
sampleswerekeptlongerthan20minafterdilution,theinhi-
bitionofY411acetylationwasnolongerobserved,suggesting
thatisoﬂurane’seﬀectwasreversible.Theobserveddiﬀerence
between immediate (330 ± 14) and delayed (653 ± 137,
P<0.05) analysis of the isoﬂurane-treated samples supports
this interpretation. It was previously shown that isoﬂurane4 Biochemistry Research International
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Figure 1: ANS binding to HSA after isoﬂurane exposure. HSA
(75μM) was exposed to isoﬂurane (0.4mM for 1.75hr at room
temperature), dialyzed, and examined for ANS binding versus
untreated control. Data are representative samples.
binds at low millimolar aﬃnity to the hydrophobic cavity
that contains the Y411 residue [3]. Our results are consistent
with the time-dependent release of isoﬂurane from the
Y411 site after dilution. Additionally, no diﬀerence was
observed between control and treated samples in maximum
Y411 acetylation (data not shown) as determined by curve
extrapolationtothe y-interceptasdescribedintheSection 2.
This also supports the notion that the binding of isoﬂurane
to this particular region of the protein is labile.
3.3. Modiﬁcation of Surface Residues on HSA. We were
also interested in examining the eﬀect of isoﬂurane on
the modiﬁcation of other HSA residues, such as surface
r e s i d u e st h a tm a yb em o d i ﬁ e db yN P Aa sw e l la sM G .
We observed that isoﬂurane increased the susceptibility of
HSA to chemical modiﬁcation by MG (Figure 4(a)). HSA
(150μM) was treated with isoﬂurane (0.3mM for 15min
at room temperature) prior to 1:10 dilution and exposure
to MG (300μM for 18.5hr at room temperature). MG-
induced ﬂuorescence (ex: 330nm; em: 380–500nm), which
is due to the formation of advanced glycation endprod-
ucts (AGEs) particularly argpyrimidine, increased by 4-
fold after isoﬂurane exposure (2.4 ± 0.03 to 9.8 ± 0.13
rfu, P<0.0005). We previously observed that isoﬂurane
increased the susceptibility of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) to MG-induced modiﬁcation [9].
Acrolein-induced modiﬁcation of HSA was also promoted
by triﬂuoroethanol that is used to mimic the eﬀects of
inhaled anesthetics on protein structure [8]. Our obser-
vations with MG represent modiﬁcations of residues that
are rather accessible, suggesting that they are exposed to
solvent and likely on the surface of the protein. The levels
of MG used in these experiments are physiological and
consistent with those previously shown to minimally modify
H S Aw i t hM G[ 22]. We also observed that rate of NPA-
induced acetylation of surface residues was also enhanced
after treatment of isoﬂurane (Figure 4(b)). HSA (150μM)
was treated with isoﬂurane (0.6mM for 60min at room
temperature) prior to 1:37.5 dilution and measurement of
acetylation rates as described in Section 2. The pseudoﬁrst-
order rate constant for acetylation (k
 
1) increased by 9% with
isoﬂurane. The observations of MG- and NPA-induced HSA
modiﬁcation (Figures 4(a) and 4(b)) represent a persistent
eﬀectofisoﬂuranethatissustainedafterdilutionanddelayed
analysis. This is consistent with the small irreversible change
in native protein conformation (Figures 1 and 2).
3.4. Changes in Electrophoretic Mobility of MG-Modiﬁed HSA
Treated with Isoﬂurane. When HSA was incubated with MG
(0.5–3.0mM for 7 days at room temperature), we observed
that the migration of the 66kDa HSA bands on SDS-
PAGE gels (7.5%) was slightly altered (Figure 5). MG caused
a similar shift in the leading edge of the HSA band in
both isoﬂurane-treated (0.3mM) and untreated samples.
However, the lagging edge diﬀered. The MG-modiﬁed HSA
band in the isoﬂurane samples appeared less diﬀuse than
control MG-modiﬁed HSA. The visual observations seen
in Figure 5(a) were substantiated upon densitometric anal-
ysis (Figure 5(b)). These results suggest that MG-induced
intramolecular crosslinking may be enhanced by isoﬂurane,
resulting in more compact denatured structures that have
slightly altered electrophoretic mobility. Additionally, there
are minor detectable amounts of high molecular weight
(HMW)bands(apparentMW:116,133,and148kDa)found
in control that may be attributed to in vivo modiﬁcations as
previously mentioned [22] that may lead to subunit-subunit
crosslinking. Further substantiation of in vivo modiﬁcations
of HSA is found in the common fructosamine blood test,
which measures serum levels of glycated albumin. We
observed that MG increased the formation of all three minor
HMW bands. The data shown in Figure 5(c) represents the
subtraction of background intensity of minus MG controls.
The increase above control suggests that these minor
HMW bands are derived from crosslinking of the major
66kDa subunit. Our current working model is that the 116
and133kDabandsrepresentcross-linkedHSAdimerspecies
and that the 148kDa represents a cross-linked HSA trimer.
This observation is consistent with the appearance of HSA
dimers and trimers at these concentrations [23]. Isoﬂurane
altered the distribution of the MG-induced HMW bands,
promoting the formation of 116 and 133kDa bands while
decreasing the formation of the 148kDa band (Figure 5(c)).
Interestingly, we previously observed that sevoﬂurane and
isoﬂurane promoted HSA dimerization while inhibiting
oligomerization, likely through anesthetic-induced trimer
destabilization [5].
4. Discussion
We report that isoﬂurane’s eﬀect on protein conformation is
persistent with isoﬂurane’s release occurring during dilution
of HSA as evidenced by ANS binding (Figure 1)a n dBiochemistry Research International 5
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Figure 2: Comparison of ﬂuorescence emission spectra after substantial dilution of HSA. Spectra before (a) and after (b) dilution: control
(solid line) and isoﬂurane-treated (dash-dotted). Data obtained from representative samples. Spectra were integrated over 310 to 400 nm to
obtain areas under the curve and compared (inset). Undiluted samples were measured at 1% attenuation of emission signal.
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Figure 3: Acetylation of residue Y411. NPA-induced acetylation
was measured following dilution of isoﬂurane-treated HSA. Sam-
ples were either analyzed immediately after dilution (black bars) or
there was a timed delay of at least 20min following dilution (gray
bars). Data are given as mean values ± SEM obtained from multiple
measurements.
W214 ﬂuorescence after dilution (Figure 2). Isoﬂurane was
previously shown to bind to this region, which is at the
interdomain cleft of HSA [3] a protein that is composed
of three homologous domains (I–III) each with two like
subdomains (A, B). W214 is found at domain IIA, which is
found adjacent to IIB at the vertex of the bilobed protein—
a region thought to be involved in oligomeric interactions
[5]. Consistent with the recovery of signal at the W214,
isoﬂurane’s inhibitory eﬀect on acetylation of Y411 was
labile and was lost upon dilution and prolonged incubation
(Figure 3). This suggests that isoﬂurane exhibits a low-
aﬃnity binding to the Y411 region, which is in domain IIIA
and known to contain a large internal hydrophobic cavity
[3]. Isoﬂurane may block Y411 acetylation that is lost upon
release of isoﬂurane from this internal pocket, which is likely
not involved in subunit-subunit interactions.
Upon extensive dilution of HSA after isoﬂurane treat-
ment, we observed a residual persistent eﬀect on the
ﬂuorescent properties of HSA (Figure 2(b)), suggesting an
irrecoverable change in conformation that is recognizable at
the W214. The total ﬂuorescence intensity of the isoﬂurane-
treated samples remained less than control, and the spectra
changed from a left-shifted to a right-shifted position com-
pared to control after extensive dilution. The spectral over-
shoot may be due structural changes that result in increased
hydration surrounding the W214 residue in domain IIA as
indicated by the postdilution right shift (Figure 2(b)). This
may represent a persistent misfold that may translate to
preconditioning signals, such as induction of stress-response
pathways. The right-shift may also reﬂect the favored
dimer conﬁguration of isoﬂurane-treated HSA as previously
suggested [5]. HSA is present as dimers and higher-order
structuresbeginningwithtrimersandprogressingincremen-
tally to tetramers, pentamers, and larger oligomers [23]. We
previously proposed that the HSA dimer occurs through
reciprocal interchange of subdomains IIA (helix 2 and 3,
residues 208–247) and IIB (helix 2 and 3, residues 323–362)
from two monomers [24], forming an isologous association.
A reconﬁguration would be required to construct multimers
via alternating interchanges resulting in a concatemeric
linkage via the internal sequences at subdomains IIA/IIB in
a heterologous association. A crosslinking study [25] using
homobifunctional linkers found a crosslink between K162 of
onesubunitandK313ofanadjacentsubunit,consistentwith
our proposed model (Figure 6).6 Biochemistry Research International
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Figure 4: Isoﬂurane increases surface residue modiﬁcation. HSA was treated with isoﬂurane prior to dilution and analysis of MG-induced
formation of AGEs (a) and NPA-induced acetylation (b). The measurements were delayed and indicate an isoﬂurane-induced eﬀect that was
not labile. Data are presented as mean values ± SD from 2–4 experiments.
Considering that isoﬂurane promotes the formation of
HSA dimers and destabilization compact oligomers [24],
one would expect an increase in the solvent-exposed surface
residues in the isoﬂurane-treated samples relative to control.
Consistentwiththismodel,weobservedthatsurfacearginine
and lysine residues on isoﬂurane-treated HSA were more
susceptible to modiﬁcation by MG and NPA than those
of control (Figure 4). There are over 80 accessible residues,
including all 59 lysine residues that are potentially modiﬁed
by NPA [16]. There are 24 arginine residues of which
ﬁve are readily modiﬁed (R114, R186, R218, R410, and
R428) [22]. MG produces several types of AGEs [21]. We
tracked the production of MG-derived AGEs that ﬂuoresce,
a characteristic typically attributed to argpyrimidine [8, 26].
These ﬂuorophores correlate with the formation of other
AGEs, such as hydroimidazolone [27], and they represent
advanced rearrangements of early unstable reaction prod-
ucts. Interestingly, host HSA from normal and diabetic
individuals contains some glycation products [22, 28]. The
surface residues on HSA described above may be associated
with regions involved in subunit-subunit interactions.
The eﬀect of isoﬂurane on these surface regions is
consistent with our previous model of the binding of inhaled
anesthetics to interfacial sites of multimeric proteins thus
altering their oligomeric states [5, 9]. The HMW bands of
HSA that migrated at 116, 133, and 148kDa may represent
MG-induced lysl-lysl or lysl-arginyl cross-linked species of
HSA. Interestingly, the distribution pattern of these three
species of MG-modiﬁed HMW bands shifted to the 116 and
133kDaspeciesinisoﬂurane-treatedHSA(Figure 5(c)).This
suggests that the 116 and 133kDa species may represent
cross-linked dimers, consistent with the observation that
isoﬂurane promotes HSA dimerization [5]. The 148kDa
species is dominant in control over isoﬂurane-treated sam-
ples, consistent with this form representing a putative
cross-linked trimer, which may have migrated further than
the expected198 kDa due to the nature of its oligomeric
conﬁguration. We previously proposed that the oligomer,
which stems from a trimeric nucleus, has a more compact
conﬁguration with screw symmetry [24]. Crosslinking along
two adjacent helical spans, for example, may constrain
the cross-linked product from become completely linear
unfolded chains under denaturing conditions, thus yielding
altered electrophoretic mobility.
Arginine residues (and secondarily lysine residues) are
the preferred nucleophilic centers for MG modiﬁcation
[21, 22]. Interestingly, four of the eight halothane binding
sites contain arginine residues (site 1: R209; site 2: R209;
site 5: R257; site 6: R218; R222) [2], suggesting that
isoﬂurane may alter the microenvironment around these
sitesaswellaspromotemoredistantconformationalchanges
that aﬀected the susceptibility to MG modiﬁcation. The
HSA monomer bands in SDS-PAGE that represent MG
modiﬁcation appeared less diﬀuse in the isoﬂurane-treated
samples (Figures 5(a) and 5(b)), suggesting that tertiary
changes in protein structure may impact the proﬁle of
residues that are modiﬁed. The reactivity of MG to the
arginine residues found near the anesthetic binding sites
may be aﬀected upon isoﬂurane binding, thus changing the
heterogeneity of the MG-modiﬁed HSA monomer bands.
Preconditioning by isoﬂurane is known to be neuropro-
tective [17, 18], suggesting that isoﬂurane may contribute to
a nonlethal “injury” that provides some beneﬁt to the host
cell. We observed that HSA, which was treated with isoﬂu-
rane and subsequently dialyzed or diluted, resulted in a per-
sistent eﬀect on protein conformation (Figures 1 and 2(b)).Biochemistry Research International 7
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Figure 5: Electrophoretic mobility of MG-modiﬁed HSA treated
with isoﬂurane. HSA was pretreated with isoﬂurane (0.3mM)
prior to dilution and exposure to MG (3mM for 7 days at room
temperature). Following SDS-PAGE, analysis of Coomassie-stained
gels involved visual inspection (a) and densitometry (b) of the
major 66kDa band. Additionally, the minor MG-induced HMW
bands (c) were analyzed by integration of densitometric scans
using SigmaGel. The densitometric analysis shown in (b) presents
the migration changes of the major bands in (a). The migration
distance in (c) represents arbitrary units of measurement that
originate from the top of the gel. The color tracings are the plus
MG samples that were treated (red) and untreated (blue) with
isoﬂurane.TheblacktracingsaretherespectiveminusMGsamples.
Isoﬂurane Isoﬂurane
(Dimer) (Oligomer)
i, j,k
(Monomer)
Figure 6: Target HSA species that are modiﬁed by MG. Our
model suggests that the HSA dimer represents an isologous
association of twofold symmetry with complementary binding
sites indicated by squares and triangles. The nucleus for further
higher-order HSA oligomerization may be a trimer [24]w i t ha
proposed screw symmetry, forming a heterologous association.
While isoﬂurane promotes dimerization [5], it may also aﬀect the
distribution of HSA dimer subpopulations (indicated by italicized
subscripts: i, j, and k). Intra- and intermolecular crosslinking by
MG (as well as surface residue acetylation) may be inﬂuenced
by subunit interaction and lead to cellular responses conferring
preconditioning.
There may be an isoﬂurane-directed protein misfold upon
dilution that may generate a conformational stress to the
cell initiating protective pathways for protein folding. Our
laboratory is currently exploring this model.
In summary, we used HSA as the surrogate protein to
examinethemolecularinteractionsassociatedwiththebind-
ing of inhaled anesthetics and changes in susceptibility to
chemical modiﬁcation. Isoﬂurane’s eﬀect on conformation
waslargelyreversiblewithasmallresidualalterationthatper-
sisted after extensive dilution. Concurrent with these eﬀects
onconformation,weobservedlabilechangesinsusceptibility
to chemical modiﬁcation as well as more persistent changes
in susceptibility involving enhanced reactivity by acetylating
agent, NPA, and glycating agent, MG. These observations
are consistent with previous ﬁndings that inhaled anesthetics
increase susceptibility of proteins to chemical modiﬁcation
[8, 9]. We also observed an isoﬂurane-dependent eﬀect that
may be, through modulation of HSA subpopulations, an
observation consistent with our previous model of inhaled
anesthetics binding to interfacial sites of multimeric proteins
[5, 9]. We think that the slight irreversible eﬀect of isoﬂurane
may represent a mechanism for preconditioning, suggesting
that isoﬂurane may induce stress-response pathways by
altering protein conformation and susceptibility to chemical
modiﬁcation.
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